Key Takeaways
- • Triomics raised $22 million in Series B funding led by Battery Ventures, bringing total capital raised to over $36 million and establishing the company as a well-capitalized player in oncology AI infrastructure.
- • The round includes participation from existing investors Nexus Venture Partners, Lightspeed, and Y Combinator, plus strategic backers Oncology Ventures and Precision Health Informatics (a subsidiary of Texas Oncology), signaling strong healthcare ecosystem validation.
- • Triomics' platform converts complex longitudinal cancer records into structured, explainable clinical intelligence, supporting patient trial matching, pre-visit chart preparation, and oncology data abstraction across care teams, research teams, and health systems.
- • The funding validates demand for AI-driven operational efficiency in oncology settings, where fragmented clinical data and manual workflows create friction in patient care and research execution.
Summary
Triomics, an oncology-focused artificial intelligence company, announced a $22 million Series B funding round led by Battery Ventures, with participation from repeat investors Nexus Venture Partners, Lightspeed, and Y Combinator. Strategic healthcare investors Oncology Ventures and Precision Health Informatics, a wholly-owned subsidiary of Texas Oncology, also participated in the round. The financing brings Triomics' cumulative capital raised to more than $36 million.
The company addresses a critical operational challenge in modern oncology: the fragmentation and complexity of cancer patient records across electronic health systems. Triomics has built a platform designed to transform unstructured, longitudinal clinical data into actionable, interpretable intelligence. The platform serves three primary use cases: patient trial matching to identify eligible candidates for clinical studies, pre-visit chart preparation to streamline clinician workflows, and oncology data abstraction to support research and quality reporting.
This Series B round reflects broader institutional confidence in AI-driven solutions for healthcare data operationalization. The participation of both venture and strategic healthcare investors—including Texas Oncology's Precision Health Informatics arm—suggests the company has achieved meaningful traction with health system customers and demonstrated clear clinical utility. For institutional investors focused on healthtech infrastructure plays, the round highlights the continued capital availability for companies solving data integration and workflow automation challenges in specialized medical domains where high regulatory standards and clinical complexity create defensible moats.
The company addresses a critical operational challenge in modern oncology: the fragmentation and complexity of cancer patient records across electronic health systems. Triomics has built a platform designed to transform unstructured, longitudinal clinical data into actionable, interpretable intelligence. The platform serves three primary use cases: patient trial matching to identify eligible candidates for clinical studies, pre-visit chart preparation to streamline clinician workflows, and oncology data abstraction to support research and quality reporting.
This Series B round reflects broader institutional confidence in AI-driven solutions for healthcare data operationalization. The participation of both venture and strategic healthcare investors—including Texas Oncology's Precision Health Informatics arm—suggests the company has achieved meaningful traction with health system customers and demonstrated clear clinical utility. For institutional investors focused on healthtech infrastructure plays, the round highlights the continued capital availability for companies solving data integration and workflow automation challenges in specialized medical domains where high regulatory standards and clinical complexity create defensible moats.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.